CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting
The poster and presentation will detail additional results from the monotherapy expansion arms of the PROCLAIM-CX-072 trial with a data cutoff date of
Poster Presentation
Abstract: #2513 / Poster Board: #157
Presenter:
Session: Developmental Immunotherapy and Tumor Immunobiology
Date/Time: Saturday, June 1, 8:00 –
Location:
The accepted abstract is available online on
Poster Discussion Session
Title: CX-072, a PD-L1 Probody Therapeutic, as Monotherapy in Patients with Advanced Solid Tumors: Preliminary Results of PROCLAIM-CX-072
Presenter:
Session: Developmental Immunotherapy and Tumor Immunobiology
Date/Time: Saturday, June 1, 1:15 –
Location:
CytomX’s poster will be available online under the Events and Presentations section of the CytomX website at the time of presentation at www.CytomX.com.
About
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. In particular, clinical and preclinical data referenced above for CX-072, including data on efficacy and safety, including treatment related adverse events, is based on a limited dataset, including for the clinical data, the limited number of patients and at specific doses and, in some cases, specific cancer types. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy of CytomX’s product candidates, administered separately or in combination, the potential benefits or applications of CytomX’s Probody platform technology, and CytomX’s ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing clinical trial of CX-072. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX’s novel Probody Platform technology; four of CytomX’s product candidates under its Probody platform are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties; the possibility that the results of early clinical trials may not be predictive of future results; the possibility that CytomX’s clinical trials will not be successful; CytomX’s dependence on the success of CX-072, CX-2009, CX-2029 and BMS 986249; CytomX’s reliance on third parties for the manufacture of the company’s product candidates; and possible regulatory developments in
Contact:
Investors and Media:
VP, Investor Relations and Corporate Communications
ckeenan@cytomx.com
650-383-0823
Source: CytomX Therapeutics Inc.